3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 1/2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Conditions
Melanoma
18
Carcinoma, Non-Small-Cell Lung
10
Carcinoma, Renal Cell
9
Kidney Neoplasms
4
Stomach Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Hepatocellular
3
Skin Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Various Advanced Cancer
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma, Cutaneous Malignant
1
Lymphatic Metastasis
1
Interventions
Cisplatin
6
Pemetrexed
4
Carboplatin
3
Nivolumab
2
Ipilimumab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
ranpirnase
1
raltitrexed
1
durvalumab
1
atezolizumab
1
Vinorelbine
1
Vincristine
1
Talc
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Platinum
1
Mitomycin
1
Injections
1
Gemcitabine
1
Fentanyl
1
Drug Therapy
1
Doxorubicin
1
Cerebral Decortication
1
Analgesia
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Mesothelioma, Malignant
×
Ipilimumab
×
Clear all
NCT06097728
2026-04-28
eVOLVE-Meso
AstraZeneca
Phase 3
Recruiting
825 enrolled
NCT04334759
2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3
Completed
214 enrolled